|
- Breast Cancer Guidelines Compared: ESMO vs NCCN - Medscape
A comparison of breast cancer guidelines from two of the world's most prominent oncology organizations, the National Comprehensive Cancer Network (NCCN) and the European Society of Medical
- New ASCO Guidelines for Advanced Ovarian Cancer - Medscape
Based on the NCCN guidelines, treatment selection for ovarian cancer is primarily determined by the histologic subtype, stage of disease, and whether the patient is a candidate for primary surgery
- FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool
The NCCN Guideline states that use of the tool for risk stratification of localized prostate cancer in clinical practice is supported by solid evidence The Category 2A recommendation signifies
- National Comprehensive Cancer Network (NCCN) 16th Annual Conference
National Comprehensive Cancer Network (NCCN) 16th Annual Conference : Read clinically focused news coverage of key developments from the meeting
- NCCN Expands Cancer Genetic Risk Assessment Guidelines - Medscape
Updates to two genetic risk assessment guidelines now include prostate, endometrial, and gastric cancer to reflect the growing understanding of hereditary cancer risk and value of genetic testing
- Adult Cancer Pain: Part 2 -- The Latest Guidelines for Pain . . . - Medscape
The NCCN uses the US Food and Drug Administration (FDA) definitions for these characteristics Opioid tolerant: patients who are taking, for 1 week or longer, at least: 60 mg oral morphine day;
- Deaths From Prostate Cancer vs Other Causes: Long-Term Data
The study estimated long-term outcomes over up to 30 years in men who received treatment for nonmetastatic prostate cancer that was in line with current National Comprehensive Cancer Network (NCCN
- NCCN Recommends Only One Genomic Test for Breast Cancer
HOLLYWOOD, Florida — The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN
|
|
|